{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:26:27Z","timestamp":1774736787407,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clbc.2020.12.013","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T17:11:27Z","timestamp":1610212287000},"page":"e402-e414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype"],"prefix":"10.1016","volume":"21","author":[{"given":"Hee Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Hwa","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hyuck","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.12.013_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0733-8619(02)00035-X","article-title":"Brain metastases","volume":"21","author":"Lassman","year":"2003","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clbc.2020.12.013_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1634\/theoncologist.8-5-398","article-title":"Diagnosis and management of central nervous system metastases from breast cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2020.12.013_bib3","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.bjc.6604941","article-title":"Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients","volume":"100","author":"Park","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.12.013_bib5","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.12.013_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10549-009-0510-2","article-title":"Patterns of relapse in breast cancer: changes over time","volume":"120","author":"Yerushalmi","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.12.013_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1006486423827","article-title":"Radiation therapy in the management of brain metastases from breast cancer","volume":"62","author":"Fokstuen","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.12.013_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-008-9578-5","article-title":"Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival","volume":"88","author":"Melisko","year":"2008","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib9","first-page":"117","article-title":"Leptomeningeal metastases in breast cancer","volume":"3","author":"Scott","year":"2013","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clbc.2020.12.013_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mdp343","article-title":"Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study","volume":"21","author":"Siena","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012226718323","article-title":"A\u00a0phase II trial of temozolomide for patients with recurrent or progressive brain metastases","volume":"53","author":"Abrey","year":"2001","journal-title":"J\u00a0Neurooncol"},{"issue":"15 Suppl","key":"10.1016\/j.clbc.2020.12.013_bib12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/jco.2009.27.15_suppl.1083","article-title":"Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC)","volume":"27","author":"Morrow","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib13","unstructured":"Murphy C, Nulsen B, Rump M, et\u00a0al. Phase II trial of patupilone in patients with breast cancer brain metastases progressing or recurring after whole brain radiotherapy. Presented as an abstract at the 2009 Breast Cancer Symposium: Abstract #234."},{"key":"10.1016\/j.clbc.2020.12.013_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-004-9176-0","article-title":"Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study","volume":"71","author":"Christodoulou","year":"2005","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib15","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ana.410380111","article-title":"Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis","volume":"38","author":"Freilich","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clbc.2020.12.013_bib17","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","article-title":"Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology","volume":"29","author":"Glass","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.clbc.2020.12.013_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.12.013_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations","volume":"129","author":"Lee","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.12.013_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.12-7-766","article-title":"Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors","volume":"12","author":"Gori","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2020.12.013_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdn682","article-title":"Survival among women with triple receptor-negative breast cancer and brain metastases","volume":"20","author":"Dawood","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib23","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/cncr.23468","article-title":"Survival in patients with brain metastases from breast cancer: the importance of HER-2 status","volume":"112","author":"Eichler","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.12.013_bib24","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr1870","article-title":"Breast cancer subtypes and survival in patients with brain metastases","volume":"10","author":"Nam","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.12.013_bib25","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2005.05.249","article-title":"Survival after brain metastases from breast cancer in the trastuzumab era","volume":"23","author":"Kirsch","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib26","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.12.013_bib27","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.12.013_bib28","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.12.013_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.07.024","article-title":"The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis","volume":"84","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092100001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092100001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:29Z","timestamp":1761513689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092100001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S152682092100001X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.12.013","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}